Understand the source comparison
Peptide Mechanisms in Telogen Effluvium vs Androgenetic Alopecia
Telogen effluvium doesn't respond to the same interventions as androgenetic aloppia because the underlying pathology is fundamentally different. In androgenetic alopecia, follicles miniaturize progressively over years due to chronic DHT exposure—the growth pha
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Telogen effluvium doesn't respond to the same interventions as androgenetic aloppia because the underlying pathology is fundamentally different. In androgenetic alopecia, follicles miniaturize progressively over years due to chronic DHT exposure—the growth phase shortens, the follicle shrinks, and eventually the hair becomes vellus. In telogen effluvium, structurally normal follicles abruptly stop growing in response to acute physiological stress: major surgery, severe infection, rapid weight loss exceeding 15% of body weight, postpartum hormonal shifts, or medication changes (particularly beta-blockers, anticoagulants, and retinoids). The follicles don't shrink—they simply transition prematurely from anagen (active growth) into telogen (resting phase), causing diffuse shedding 8–12 weeks later when those resting hairs detach.
- The peptides studied for telogen effluvium target three distinct intervention points: copper peptides like GHK-Cu bind to copper ions and stimulate fibroblast growth factor production, which signals quiescent follicles to re-enter anagen; TB-500 (a synthetic fragment of Thymosin Beta-4) modulates inflammatory cytokines at the follicle level, reducing the pro-apoptotic signals that force early telogen transition; PTD-DBM peptides (protein transduction domain-mediated delivery of growth factors) activate Wnt/β-catenin signaling in dermal papilla stem cells, the population responsible for initiating new hair cycles. None of these mechanisms involve androgen receptor activity or blood flow modulation.
- Our experience reviewing peptide protocols for research applications has shown that the most common error is applying peptides studied exclusively in androgenetic alopecia models (where chronic DHT exposure is the driver) to telogen effluvium cases (where acute stress is the driver). A 2019 study published in the Journal of Cosmetic Dermatology tested GHK-Cu topically in 30 patients with chronic telogen effluvium (persisting beyond 6 months) and found significant improvement in hair density at 12 weeks—but the mechanism was entirely independent of DHT inhibition. The copper peptide increased expression of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), both of which are suppressed during acute stress responses and are required for anagen re-entry.